Development and internal validation of a predictive model of overall and progression-free survival in eribulin-treated patients with breast cancer based on baseline peripheral blood parameters

• DOI: 10.1007/s12282-025-01678-7
• Publication Date: 2025-02-20T16:31:21Z
• Authors: Keiko Natori; Masataka Igeta; Takashi Morimoto; Masayuki Nagahashi; Sadako Akashi-Tanaka; Takashi Daimon; Yasuo Miyoshi
• Keywords: Eribulin; Surgical oncology; Angiology

Immune and inflammatory blood parameters have been reported as biomarkers for treatment efficacy. This study aimed to establish a predictive model that includes patients with metastatic breast cancer treated eribulin. A total of 297 were enrolled, their baseline neutrophil-to-lymphocyte ratio, absolute lymphocyte count (ALC), platelet-to-lymphocyte ratio (PLR), prognostic nutritional index (PNI), lymphocyte-to-monocyte (LMR), lactate dehydrogenase (LDH), C-reactive protein (CRP), clinical data retrospectively collected. We constructed nomograms predict overall survival (OS) progression-free (PFS) using parameters, including factors. For OS, menopausal status, hormone receptor HER2 de novo or recurrent, site, line, ALC, PLR, PNI, LMR, LDH, CRP selected the model. used PFS. Both OS PFS according risk scores significantly different (p < 0.001). The optimism-corrected C-indices 0.680 0.622, respectively. mean time-dependent area under receiver operating curve values at 1, 2, 3 years 0.752, 0.761, 0.784, respectively, 3, 6, 12 months 0.660, 0.661, 0.650, Nomograms incorporating peripheral may improve accuracy predicting in Our prediction help decision-making who are considering eribulin treatment.